))
Optimizing Biomarker Testing to Guide Treatment Selection for Metastatic Colorectal Cancer
Manage episode 429354616 series 3381434
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
CME credits: 1.00
Valid until: 16-11-2024
Claim your CME credit at https://reachmd.com/programs/project-oncology/program-name/26365/
This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing procedures, and the role of biomarkers in guiding treatment selection. Case vignettes will provide the basis for expert faculty discussions that explore ways to address common barriers to biomarker testing, benefits of tissue versus liquid biopsy, when to test and why, and the use of biomarkers in prediction and prognosis. Finally, individualizing the treatment of mCRC based on molecular (eg, RAS, BRAF, MSI-high, HER2), patient (eg, comorbidities, age), and tumor (location, resectability) characteristics, as well as patient preferences (quality of life, treatment toxicities) will be discussed.=
…
continue reading
Valid until: 16-11-2024
Claim your CME credit at https://reachmd.com/programs/project-oncology/program-name/26365/
This 1.0-credit activity provides oncology clinicians with practical insights into the importance of biomarker testing in patients diagnosed with metastatic colorectal cancer (mCRC), optimizing biomarker testing procedures, and the role of biomarkers in guiding treatment selection. Case vignettes will provide the basis for expert faculty discussions that explore ways to address common barriers to biomarker testing, benefits of tissue versus liquid biopsy, when to test and why, and the use of biomarkers in prediction and prognosis. Finally, individualizing the treatment of mCRC based on molecular (eg, RAS, BRAF, MSI-high, HER2), patient (eg, comorbidities, age), and tumor (location, resectability) characteristics, as well as patient preferences (quality of life, treatment toxicities) will be discussed.=
594 episodes
Share
